Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Bone metastasis: the importance of the neighbourhood
2016352 citationsPeter I. Croucher et al.profile →
The dormant cancer cell life cycle
2020349 citationsTri Giang Phan, Peter I. Croucherprofile →
Bone metastases
2020347 citationsPeter I. Croucher et al.profile →
Author Peers
Peers are selected by citation overlap in the author's most active subfields.
citations ·
hero ref
Countries citing papers authored by Peter I. Croucher
Since
Specialization
Citations
This map shows the geographic impact of Peter I. Croucher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter I. Croucher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter I. Croucher more than expected).
Fields of papers citing papers by Peter I. Croucher
This network shows the impact of papers produced by Peter I. Croucher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter I. Croucher. The network helps show where Peter I. Croucher may publish in the future.
Co-authorship network of co-authors of Peter I. Croucher
This figure shows the co-authorship network connecting the top 25 collaborators of Peter I. Croucher.
A scholar is included among the top collaborators of Peter I. Croucher based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Peter I. Croucher. Peter I. Croucher is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Laurent, Lætitia, Sirui Zhou, Vincenzo Forgetta, et al.. (2019). Identification and Validation of Targets for Osteoporosis: Evidence from Whole exome Sequencing in 42,263 individuals, CRISPR-Cas9 and murine models. Queensland's institutional digital repository (The University of Queensland).1 indexed citations
Esapa, Christopher T., Michael Cheeseman, Tertius Hough, et al.. (2009). A mouse with a Trp589Arg mutation in N-acetylgalactosaminyltransferase 3 (Galnt3) provides a model for familial tumoural calcinosis. 19.1 indexed citations
11.
Locklin, Rachel M., Ermanno Federici, Peter I. Croucher, R.G.G. Russell, & C M Shipman. (2005). Differential sensitivity of normal osteoblast-like cells and osteosarcoma cells to TRAIL and an agonist antibody to TRAIL receptor-2. Journal of Bone and Mineral Research. 20. 1307–1307.1 indexed citations
12.
Valckenborgh, Els Van, Peter I. Croucher, Hendrik De Raeve, et al.. (2004). Multifunctional role of matrix metalloproteinases in multiple myeloma: study in the 5T2mm mouse model.. VUBIR (Vrije Universiteit Brussel).1 indexed citations
13.
Eaton, Colby L., et al.. (2004). Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients. Journal of Bone and Mineral Research. 19. 1585–1585.1 indexed citations
14.
Holen, Ingunn, Peter I. Croucher, Anthony C. Evans, et al.. (2002). OPG is a survival factor for breast- and prostate cancer cells in vitro. Bone. 30.1 indexed citations
15.
Leenheer, Evy De, Karin Vanderkerken, Marleen Bâkkus, et al.. (2002). Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.. Blood. 100.2 indexed citations
16.
Croucher, Peter I., C M Shipman, Mark Perry, et al.. (2001). Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Bone. 28(5).1 indexed citations
17.
Croucher, Peter I., C M Shipman, Mark Perry, et al.. (2001). Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma. Blood. 98.6 indexed citations
18.
Croucher, Peter I., C M Shipman, Mark Perry, et al.. (2000). Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.. Blood. 96(11).1 indexed citations
19.
Shipman, C M, et al.. (2000). Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.. Journal of Bone and Mineral Research. 15. 1217–1217.2 indexed citations
20.
Shipman, C M, Ingunn Holen, J M Lippitt, Elisabeth Vandenberghe, & Peter I. Croucher. (2000). Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.. Blood. 96.13 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.